University of Hawaii at Manoa Homepage

News Highlights

August 16, 2017

Finding Potentially Improves Standard Mesothelioma Treatment

HONOLULU – University of Hawai'i Cancer Center researchers found that targeting chromosomal instability in mesothelioma, a very malignant cancer of the lining of the chest and abdomen often caused by asbestos, improves response to standard chemotherapies.

The study published in Oncogene found that a new drug known as CFI-402257 suppresses mesothelioma growth. The drug, synergized with the current standard of care for mesothelioma (Cisplatin/Pemetrexed therapy), reduced the growth of human mesothelioma cells thereby increasing the efficacy of the current standard of care. The preclinical findings indicated that CFI-402257 is a promising new therapeutic agent to improve current chemotherapeutic regimens for mesothelioma patients.

"We continue to search for weaknesses of mesothelioma cancer cells that can be exploited to improve current therapies for mesothelioma," said Dr. Haining Yang, senior author.

The research was coordinated and conducted in Hawai'i by Drs. Haining Yang and Michele Carbone at the UH Cancer Center, and in collaboration with the team of Dr. Tak Mak, at the University of Toronto.

Publication: Oncogene: Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma
DOI: 10.1038/onc.2017.266

The University of Hawai'i Cancer Center through its various activities, cancer trial patients and their guests, and other visitors adds more than $54 million to the O'ahu economy. It is one of only 69 research institutions designated by the National Cancer Institute. Affiliated with the University of Hawai'i at Mānoa, the Center is dedicated to eliminating cancer through research, education, patient care and community outreach with an emphasis on the unique ethnic, cultural, and environmental characteristics of Hawai'i and the Pacific.
Learn more at www.uhcancercenter.org. Like us on Facebook at www.facebook.com/UHCancerCenter. Follow us on Twitter @UHCancerCenter.

Back»